Friday, 16 October 2026European Markets

CTC ORD SHARES Stock Is 10% Down So Far Today

Loading stream...

(VIANEWS) - Shares of CTC ORD SHARES (AEX-Index: CTCA1.AS) dropped by a staggering 10.53% to €8.50 at 14:07 EST on Wednesday, after five successive sessions in a row of losses. AEX-Index is sliding 0.72% to €773.14, after five consecutive sessions in a row of gains. This seems, as yet, a somewhat bearish trend exchanging session today.

CTC ORD SHARES's last close was €9.50, 5% below its 52-week high of €10.00.

About CTC ORD SHARES

Climate Transition Capital Acquisition I B.V., a special purpose acquisition company, intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with businesses or entities. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, CTC ORD SHARES has a trailing twelve months EPS of €-0.46.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CTC ORD SHARES's stock is considered to be overbought (>=80).

Moving Average

CTC ORD SHARES's value is way below its 50-day moving average of €9.84 and way below its 200-day moving average of €9.83.

Yearly Top and Bottom Value

CTC ORD SHARES's stock is valued at €8.50 at 14:07 EST, way below its 52-week low of €9.55.

More news about CTC ORD SHARES (CTCA1.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com